Systematic review of 24 articles (9 in a network meta-analysis; 8 trials, n=6248) in metastatic hormone-sensitive prostate cancer: at 12 months ADT + abiraterone was linked to less pain than ADT + placebo, apalutamide or enzalutamide, and the best quality-of-life profile.
Meta-analysisn = 6,248
van Elst et al. Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysis